ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure

For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.

Corresponding placebo: matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan.